(Q35677025)

9 August 2017

title

Discoid lupus erythematosus-like eruption induced by infliximab (English)

1 reference

9 August 2017

Stratigos AJ

1

1 reference

9 August 2017

Antoniou C

2

1 reference

9 August 2017

Stamathioudaki S

3

1 reference

9 August 2017

Avgerinou G

4

1 reference

9 August 2017

Tsega A

5

1 reference

9 August 2017

Katsambas AD

6

1 reference

9 August 2017

publication date

1 March 2004

1 reference

Clinical and Experimental Dermatology

9 August 2017

published in

1 reference

9 August 2017

volume

29

1 reference

9 August 2017

issue

2

1 reference

9 August 2017

page(s)

150-153

1 reference

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2004.01471.X

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2004.01471.X

New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2004.01471.X

Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2004.01471.X

Reduced expression of CD44 on monocytes and neutrophils in systemic lupus erythematosus: relations with apoptotic neutrophils and disease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2004.01471.X

Adverse reactions to TNF-α inhibitors in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2004.01471.X

Infliximab-induced systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2004.01471.X

Anti-TNF-alpha-induced systemic lupus syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2004.01471.X

Drug-induced systemic lupus erythematosus associated with etanercept therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2004.01471.X

Autoimmune skin rashes associated with etanercept for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2004.01471.X

Dermatological complications of etanercept therapy for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2004.01471.X

Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2004.01471.X

In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2230.2004.01471.X

10.1111/J.1365-2230.2004.01471.X

21 January 2018

Identifiers

DOI

1 reference

9 August 2017

1 reference